Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats

Physiological Reports

Volumn 3, Issue 12, 2015, Pages

  Hirata, Michinori ^a   Tashiro, Yoshihito ^a   Aizawa, Ken ^a   Kawasaki, Ryohei ^a   Shimonaka, Yasushi ^a   Endo, Koichi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CERA; Epoetin beta pegol (continuous erythropoietin receptor activator; Hepcidin 25; Iron deposition; Liver type fatty acid binding protein (L FABP)

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; IRON; MONOCLONAL ANTIBODY;

ACUTE GLOMERULONEPHRITIS; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; IRON URINE LEVEL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; OXIDATIVE STRESS; RAT; UREA NITROGEN BLOOD LEVEL;

EID: 85006046086     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12637     Document Type: Article

References (27)

1. Aizawa, K., S. Takeda, Y. Tashiro, K. Yorozu, M. Hirata, H. Kanada, et al. 2012. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am. J. Nephrol. 36:419-426.
2. Aizawa, K., Y. Tashiro, M. Hirata, S. Takeda, R. Kawasaki, and K. Endo. 2014. Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats. J. Nephrol. 27:395-401.
3. Bahlmann, F. H., and D. Fliser. 2009. Erythropoietin and renoprotection. Curr. Opin. Nephrol. Hypertens. 18:15-20.
4. Barratt, J., and J. Feehally. 2006. Treatment of IgA nephropathy. Kidney Int. 69:1934-1938.
5. Canadillas, S., R. Ortega, J. C. Estepa, J. Egea, A. Gonzalez-Menchen, C. Perez-Seoane, et al. 2010. Darbepoetin-alpha treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model. Am. J. Physiol. Renal. Physiol. 299:F1278-F1287.
6. Drueke, T. B., F. Locatelli, N. Clyne, K. U. Eckardt, I. C. Macdougall, D. Tsakiris, et al. 2006. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355:2071-2084.
7. Fliser, D., F. H. Bahlmann, and H. Haller. 2006. EPO: renoprotection beyond anemia correction. Pediatr. Nephrol. 21:1785-1789.
8. Gouva, C., P. Nikolopoulos, J. P. Ioannidis, and K. C. Siamopoulos. 2004. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 66:753-760.
9. Gutierrez, E., J. Egido, A. Rubio-Navarro, I. Buendia, L. M. Blanco Colio, O. Toldos, et al. 2012. Oxidative stress, macrophage infiltration and CD163 expression are determinants of long-term renal outcome in macrohematuria-induced acute kidney injury of IgA nephropathy. Nephron Clin. Pract. 121:c42-c53.
10. Harris, D. C., C. Tay, and B. J. Nankivell. 1994. Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin. Exp. Pharmacol. Physiol. 21:73-81.
11. Izuhara, Y., M. Nangaku, R. Inagi, N. Tominaga, T. Aizawa, K. Kurokawa, et al. 2005. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J. Am. Soc. Nephrol. 16:3631-3641.
12. Johnson, D. W., B. Pat, D. A. Vesey, Z. Guan, Z. Endre, and G. C. Gobe. 2006. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 69:1806-1813.
13. Katavetin, P., R. Inagi, T. Miyata, J. Shao, R. Sassa, S. Adler, et al. 2007. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem. Biophys. Res. Commun. 359:928-934.
14. Kuriyama, S., H. Tomonari, H. Yoshida, T. Hashimoto, Y. Kawaguchi, and O. Sakai. 1997. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185.
15. Moreno, J. A., C. Martin-Cleary, E. Gutierrez, O. Toldos, L. M. Blanco-Colio, M. Praga, et al. 2012. AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences. Clin. J. Am. Soc. Nephrol. 7:175-184.
16. Naito, Y., A. Fujii, H. Sawada, S. Hirotani, T. Iwasaku, A. Eguchi, et al. 2012. Effect of iron restriction on renal damage and mineralocorticoid receptor signaling in a rat model of chronic kidney disease. J. Hypertens. 30:2192-2201.
17. Nankivell, B. J., J. Chen, R. A. Boadle, and D. C. Harris. 1994. The role of tubular iron accumulation in the remnant kidney. J. Am. Soc. Nephrol. 4:1598-1607.
18. Ostendorf, T., U. Kunter, H. J. Grone, F. Bahlmann, H. Kawachi, F. Shimizu, et al. 2001. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 12:909-918.
19. Raij, L., S. Azar, and W. Keane. 1984. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 26:137-143.
20. Rodrigues, C. E., T. R. Sanches, R. A. Volpini, M. H. Shimizu, P. S. Kuriki, N. O. Camara, et al. 2012. Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction. PLoS ONE 7:e29893.
21. Sasaki, Y., M. Noguchi-Sasaki, H. Yasuno, K. Yorozu, and Y. Shimonaka. 2012. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int. J. Hematol. 96:692-700.
22. Shah, S. V., R. Baliga, M. Rajapurkar, and V. A. Fonseca. 2007. Oxidants in chronic kidney disease. J. Am. Soc. Nephrol. 18:16-28.
23. Sharples, E. J., N. Patel, P. Brown, K. Stewart, H. Mota-Philipe, M. Sheaff, et al. 2004. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J. Am. Soc. Nephrol. 15:2115-2124.
24. Singh, A. K., L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson, et al.; CHOIR Investigators. 2006. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355:2085-2098.
25. Tsuji, M., T. Monkawa, J. Yoshino, M. Asai, S. Fukuda, H. Kawachi, et al. 2006. Microarray analysis of a reversible model and an irreversible model of anti-Thy-1 nephritis. Kidney Int. 69:996-1004.
26. Wang, H., K. Nishiya, H. Ito, T. Hosokawa, K. Hashimoto, and T. Moriki. 2001. Iron deposition in renal biopsy specimens from patients with kidney diseases. Am. J. Kidney Dis. 38:1038-1044.
27. Wang, G., Y. Gong, J. Anderson, D. Sun, G. Minuk, M. S. Roberts, et al. 2005. Antioxidative function of L-FABP in LFABP stably transfected Chang liver cells. Hepatology 42:871-879